INCY News and Press, Incyte Corporation From 02/10/23

- Results from open-label extension period of the Phase 2 trial demonstrate that longer-term treatment with povorcitinib 75 mg resulted in sustained and durable efficacy across all treatment arms - Data featured as an oral presentation at the European Hidradenitis Suppurativa Foundation...

Incyte ( NASDAQ: INCY ) is down 5% in Tuesday morning after reporting Q4 2022 earnings results that some Street analysts were less than impressed with. Although the biopharma beat on the top and bottom lines , several analysts took issue with what they see as conservative 2023...

Incyte Corporation (INCY) Q4 2022 Earnings Conference Call February 7, 2023 8:00 AM ET Company Participants Christine Chiou - Head, Investor Relations Hervé Hoppenot - Chairman, President and Chief Executive Officer Barry Flannelly - Executive Vice President and G...

Incyte press release ( NASDAQ: INCY ): Q4 Non-GAAP EPS of $0.62 beats by $0.05 . Revenue of $926.7M (+7.4% Y/Y) beats by $46.45M . For further details see: Incyte Non-GAAP EPS of $0.62 beats by $0.05, revenue of $926.7M beats by $46.45M

– Total FY'22 net product revenues grew 18% to $2.75 billion; total FY'22 revenues of $3.4 billion (+14% Y/Y) – Jakafi ® (ruxolitinib) net revenues of $647 million (+9% Y/Y) in Q4'22 and $2.41 billion (+13%) in FY'22; Jakafi net revenues guidance range of $2.53 - ...

Summary BriaCell Therapeutics Corp. is a clinical-stage biotechnology company specializing in targeted novel immuno-therapies to fight breast and prostate cancer. The FDA has agreed on the registration study design which will enroll advanced metastatic breast cancer patients for whom no...

Many economic analysts continue to predict that a recession will hit the U.S. economy sometime in 2023. Equity markets already experienced a downturn last year due partly to economic troubles, so the possibility of a recession seems even more daunting than it otherwise would be. However, the...

Summary MorphoSys AG is a German commercial-stage biopharmaceutical company founded in 1992 with more than 100+ pipeline candidates. We believe MorphoSys's two key value drivers are a) monjuvi and b) pelabresib. We expect Monjuvi's sales to continue to falter. There are no short...

Piper Sandler has initiated Incyte ( NASDAQ: INCY ) with an overweight rating saying the biopharma's diverification into dermatology provides a new avenue for growth. The firm has a $100 price target (~20% upside based on Monday's close). Analyst Allison Bratzel says that revenue ...

Summary ARK Invest’s 13F portfolio value decreased from $14.35B to $11.54B this quarter. They increased Tesla, Ginkgo Bioworks, and Coinbase Global stakes while decreasing NVIDIA, Fate Therapeutics, and TuSimple Holdings during the quarter. The top three positions are Exact S...